@article{b54a13784705402ca839fb6e9ed83e58,
title = "An update on adjunctive treatment options for bipolar disorder",
abstract = "Objectives: Bipolar disorder is a complex illness often requiring combinations of therapies to successfully treat symptoms. In recent years, there have been significant advancements in a number of therapies for bipolar disorder. It is therefore timely to provide an overview of current adjunctive therapeutic options to help treating clinicians to inform their patients and work towards optimal outcomes. Methods: Publications were identified from PubMed searches on bipolar disorder and pharmacotherapy, nutraceuticals, hormone therapy, psychoeducation, interpersonal and social rhythm therapy, cognitive remediation, mindfulness, e-Health and brain stimulation techniques. Relevant articles in these areas were selected for further review. This paper provides a narrative review of adjunctive treatment options and is not a systematic review of the literature. Results: A number of pharmacotherapeutic, psychological and neuromodulation treatment options are available. These have varying efficacy but all have shown benefit to people with bipolar disorder. Due to the complex nature of treating the disorder, combination treatments are often required. Adjunctive treatments to traditional pharmacological and psychological therapies are proving useful in closing the gap between initial symptom remission and full functional recovery. Conclusions: Given that response to monotherapy is often inadequate, combination regimens for bipolar disorder are typical. Correspondingly, psychiatric research is working towards a better understanding of the disorder's underlying biology. Therefore, treatment options are changing and adjunctive therapies are being increasingly recognized as providing significant tools to improve patient outcomes. Towards this end, this paper provides an overview of novel treatments that may improve clinical outcomes for people with bipolar disorder.",
keywords = "bipolar disorder, cognition, e-health, hormones, neuromodulation techniques, nutraceuticals, psychological therapies, transcranial magnetic stimulation",
author = "Olivia Dean and Emma Gliddon and {Van Rheenen}, {Tamsyn E} and Francesco Giorlando and Davidson, {Sandra K} and Manreena Kaur and Trung Ngo and Williams, {Lana J.}",
note = "Funding Information: EG acknowledges the funding support of the Ian Parker Bipolar Research Fund and Australian Rotary Health. TEVR, SKD and MK would each like to acknowledge the support of an NHMRC Early Career Fellowship. LJW would like to acknowledge the support of an NHMRC Career Development Fellowship. Funding Information: OMD has received grant support from the Brain & Behavior Research Foundation. FOMD has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC and ASBDD/Servier. She has also received in kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. EG has received a scholarship from the Ian Parker Bipolar Research Fund and Australian Rotary Health. TEVR is supported by an NHMRC Early Career Fellowship. She has received funding from the Helen McPherson Smith Trust, Swinburne University, University of Melbourne, Society of Mental Health Research, Rebecca L. Cooper Foundation and Jack Brockhoff Foundation. FG has received scholarships from the University of Melbourne (Melbourne Research Scholarship) and ASBDD/AstraZeneca Scholarship. He has also received a Pfizer Neuroscience Research Grant and a Royal Australian and New Zealand College of Psychiatrists (RANZCP) Young Investigator Grant. SKD is supported by an NHMRC Early Career Fellowship. She has also received funding from beyondblue, the Melbourne Networked Society Institute and the NHMRC. MK is supported by an NHMRC Early Career Fellowship and has received funding through a Society for Mental Health Research-Medibank Early Career Award and Monash University. TTN has received funding support from NHMRC (IDs 490976 and 580003), the Defence Health Foundation, and the Brain & Behavior Research Foundation (ID 19163). LJW has received grant/research support from Eli Lilly, Pfizer, The University of Melbourne, Deakin University and the NHMRC, and is supported by an NHMRC Career Development Fellowship (GNT1064272). All authors (except OMD, SKD and MK) belong to the Australasian Society for Bipolar and Depressive Disorders Early/Mid-Career Subcommittee. Funding Information: Ian Parker Bipolar Research Fund; Australian Rotary Health; NHMRC Early Career Fellowship; NHMRC Career Development Publisher Copyright: {\textcopyright} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2018",
month = mar,
doi = "10.1111/bdi.12601",
language = "English",
volume = "20",
pages = "87--96",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Wiley-Blackwell",
number = "2",
}